查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1844066

腦腫瘤診斷和治療市場（按治療方法、影像技術、最終用戶、腫瘤類型、腫瘤分級和患者年齡層分類）－全球預測，2025-2032年

Brain Tumor Diagnosis & Therapeutics Market by Therapeutic Modality, Imaging Technology, End User, Tumor Type, Tumor Grade, Patient Age Group - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 196 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，腦腫瘤診斷和治療市場規模將達到 37.3 億美元，複合年成長率為 9.65%。

關鍵市場統計數據
基準年 2024 17.8億美元
預計年份：2025年 19.5億美元
預測年份 2032 37.3億美元
複合年成長率 (%) 9.65%

本書清晰而有力地介紹了影響腦腫瘤診斷和治療創新發展的臨床、科學和衛生系統因素。

腦腫瘤的診斷和治療方法正處於臨床緊迫性、科學創新和醫療體系轉型三者快速交會的階段。分子生物學和診斷影像技術的進步正在重新定義臨床醫生對腫瘤的分類方式，從而實現更精準的診斷分類，為個人化治療策略提供基礎。同時，不斷發展的外科手術技術、輔助放射治療方法以及日益增多的標靶治療和免疫療法正在重塑不同腫瘤類型和年齡層患者的治療路徑。

這一領域由神經外科醫師、神經腫瘤科醫師、放射科醫師、病理學家、轉化科學家等多學科協作所構成。基因組分析、先進的磁振造影定序和功能性影像等技術的融合，為風險適應性治療和更明智的臨床決策提供了支持。然而，仍有大量未滿足的醫療需求，尤其是在侵襲性腫瘤和罕見的兒童變異型腫瘤方面，這些腫瘤的持久療效有限，治療選擇也十分狹窄。

因此，相關人員方正優先考慮診斷和治療的整合開發，重點關注生物標記主導的臨床試驗、微創監測和真實世界證據的生成。本報告介紹了當前臨床實踐的關鍵主題、技術創新的發展軌跡以及醫療保健系統的應用，為後續的詳細分析奠定了基礎，並為開發人員、醫療服務提供者和支付方組裝了切實可行的建議。

對正在重新定義整體醫療保健領域腦腫瘤診斷和治療方法發展的主要技術、臨床和護理服務變革進行深入分析。

腦瘤的診斷和治療方法領域正經歷多項變革性變化，這些變化共同改變了醫療服務的提供方式和產品的研發方向。在診斷層面，高解析度影像和分子病理學技術使得超越說明分類的精確表現型分析成為可能。同時，免疫腫瘤學和細胞治療方法正從實驗平台發展成為可行的臨床治療方案，引發了人們對安全性監測、生產規模和長期追蹤等方面的新思考。

影像學領域的創新，包括擴散張量成像、功能性磁振造影和氨基酸正子斷層掃描示踪劑，提高了病灶的定性分析和治療計劃的製定，從而實現了更保守的切除和更最佳化的放射治療靶向。外科手術的進步，例如術中可視化和螢光引導切除，在保留功能的同時擴大了切除範圍，從而改變了輔助性治療的決策。在治療方面，標靶藥物與免疫調節療法結合的聯合治療已成為臨床研發的重點，這需要更精細的生物標記策略和伴隨診斷技術。

此外，數位健康、機器學習和真實世界數據正逐漸成為早期檢測、預後建模和上市後監測的工具。這種轉變既帶來了機遇，也帶來了挑戰。開發者必須應對監管機構對新型療法的期望，而醫療系統則必須調整基礎設施以支援多學科工作流程和先進的診斷技術。從孤立的創新模式轉向整合式醫療路徑，將決定哪些技術進步能真正改善病患的治療效果。

評估近期關稅主導的貿易行動可能如何重塑美國腦腫瘤診斷和治療藥物的供應鏈、採購和應用動態

關稅等政策干預措施會對支持腦腫瘤診斷和治療的生態系統產生廣泛而累積的影響。影響成像設備、分子檢測試劑以及用於先進外科手術和細胞療法生產的專用耗材的進口措施，會增加直接採購成本，並延長關鍵工具的前置作業時間。這些壓力會波及醫院的資本規劃和臨床試驗的後勤保障，減緩新型診斷平台的普及，並限制先進治療方法的推廣速度。

製造商和醫療系統可能會透過加快供應鏈本地化和投資國內高價值投入品的生產能力來應對。雖然將生產遷回國內可以緩解未來貿易相關的衝擊，但這需要大量的資本投入和策略夥伴關係關係來確保品質和合規性。對於規模較小的開發商和學術機構而言，不斷上漲的進口成本可能會促使他們優先考慮資本密集度較低的技術和能夠減少初始硬體需求的授權合約。

在研究領域，關稅可能會改變依賴統一成像和分子平台的多中心臨床試驗的經濟效益，使數據協調和可比性變得複雜。臨床合作者可能需要重新協商服務協議或調整通訊協定以應對設備差異。最終，相關人員應將關稅相關影響視為推動供應多元化、策略採購以及產業、臨床網路和政策制定者之間更緊密合作的催化劑，以保障關鍵診斷和治療創新成果的可及性。

深入的細分綜合分析表明，治療方式、影像技術創新、終端用戶、腫瘤類型、分級和患者人口統計特徵如何反映策略重點。

從細分觀點出發，可以更清楚地了解診斷和治療領域中科學進步和機會的交會點。化療包括烷化劑、抗代謝藥物和鉑類化合物，這些藥物仍然是許多治療方案的核心。同時，標靶治療則著重於分子脆弱性的藥物，例如抗血管新生藥物、mTOR抑制劑和蛋白酪氨酸激酶抑制劑。免疫療法包括CAR-T細胞療法、查核點抑制劑和疫苗平台，這些療法推動了聯合治療策略的發展，並需要專門的生產和安全性監測。這些治療方法與腫瘤生物學和患者因素相互作用，從而影響治療順序和試驗設計。

在診斷影像領域，市場由CT（電腦斷層掃描）、MRI（磁振造影）、分子診斷、PET（正子斷層掃描）和超音波細分市場所構成。磁振造影可進一步細分為擴散張量造影、功能性磁振造影和波譜分析，這些技術能夠增強結構和功能評估；而正子斷層掃描則利用胺基酸示蹤劑和FDG來改善代謝評估。終端使用者包括門診手術中心、診斷實驗室、醫院和研究機構，它們在資本密集度、工作流程需求和技術實施決策方面各不相同。

腫瘤類型可分為聽神經瘤、膠質瘤、腦膜瘤和腦下垂體瘤，這些腫瘤有不同的臨床病程和調控路徑。腫瘤分級分為高級別和低級別，這對於預後和治療強度至關重要。患者年齡層——成人、老年和兒童——帶來了不同的生物學考量、劑量需求和監管保護，尤其是在兒童群體中，長期神經認知結果至關重要。整合這些細分視角，可以揭示在分子標靶標靶生物學、未滿足的臨床需求和可行的給藥途徑的交匯點上，投資和臨床重點應該放在哪裡。

全面的區域分析顯示了美洲、歐洲、中東和非洲以及亞太地區各自如何影響臨床應用、監管策略和商業化路徑。

地理動態是技術採納、監管路徑和商業策略的關鍵決定因素。在美洲，臨床試驗能力、創投和整合醫療網路，以及強大的生物技術轉化生態系統和先進的醫院基礎設施，正在促進新型診斷和治療方法的快速應用。美國尤其如此，它仍然是早期臨床試驗和商業性上市的重點，但區域報銷和政策差異會影響產品上市的速度。

歐洲、中東和非洲地區（EMEA）擁有領先的神經腫瘤中心，部分地區甚至擁有國家級研究網路，但其醫療保健系統和法規環境卻存在差異。歐洲的法規結構強調嚴格的證據和成本效益，而海灣地區和北非的一些市場則大力投資於三級醫療，對高價值治療方案產生了選擇性需求。這些差異要求制定量身定做的打入市場策略和針對特定區域的證據產生方案。

亞太地區都市區化進程迅速，國內製造業產能不斷成長，人口結構變化推動了對神經腫瘤服務的需求。該地區對成本高度敏感且報銷機制多樣，因此需要彈性價格設定和合作模式。同時，由於患者數量龐大且營運效率高，一些亞洲國家正成為後期臨床試驗的關鍵地點。跨區域合作和技術轉移對於確保全球醫療標準的一致性和創新規模發展至關重要。

提供可操作的企業資料，概述策略夥伴關係、平台整合和製造投資如何使腦腫瘤診斷和治療開發公司脫穎而出。

該領域的企業活動以策略夥伴關係、平台拓展以及對生產製造和數位化能力的定向投資為特徵。將診斷平台與其治療產品線整合或實現伴隨診斷關聯的企業，將透過協調研發和商業化時間表來獲得競爭優勢。生物製藥開發商與診斷和影像供應商之間的合作日益受到生物標記主導的患者招募和即時療效評估需求的推動。

關鍵的企業策略包括組成聯盟以降低早期臨床開發的風險、將細胞和基因療法的專業生產外包，以及投資於用於成像和長期療效監測的雲端基礎平台。併購仍然是快速獲取能力的一種手段，尤其對於那些尋求整合分子檢測、成像和臨床決策支援以提供統一產品的公司而言更是如此。規模較小的創新企業經常透過收購或簽訂共同開發契約來擴展其生產和監管方面的專業知識，而規模較大的企業則專注於平台整合和全球市場滲透。

在競爭激烈的市場環境中，建立與支付方關係和展現醫療經濟價值的敏捷性與科學差異化同等重要。那些積極應對實際應用挑戰、簡化臨床工作流程並為醫療服務提供者提供培訓和支援的公司，更有可能實現持續的市場認可和商業性成功。

為產業領導者提供清晰、優先的建議，以加速腦腫瘤治療的研發，降低商業性風險，並展現其臨床和經濟價值。

產業領導者應採取一系列切實可行的優先事項，將科學前景轉化為臨床影響和永續的經營模式。首先，應優先投資於整合診斷技術，將分子譜分析與先進影像技術結合，以實現精準的病患篩選和適應性臨床試驗招募。這種方法可以降低研發風險，並提高展現顯著臨床效益的可能性。其次，應實現供應鏈多元化，並探索區域製造夥伴關係，以減輕貿易和關稅的影響，同時確保價值鏈的連續性。

第三，我們將有意推行聯合策略，在研發早期階段協調監管和安全路徑，並建立標準化的生物標記策略，以簡化核准和報銷流程。第四，我們將儘早與支付方和衛生技術評估機構合作，明確支持基於價值的合約的證據要求和病例定義。第五，我們將投資於真實世界證據和數據基礎設施，以收集長期結果、生活品質指標和衛生經濟學終點，從而支持藥物的推廣應用和納入處方實踐。

最後，應加強與學術中心、病患權益組織以及外科和放射科網路的跨部門合作，以加速臨床應用，改善臨床試驗招募，並確保創新能解決實際醫療服務中的限制。採取這些措施有助於機構縮短產品上市時間，強化價值論證，最終改善複雜治療領域的患者預後。

嚴謹透明的調查方法，結合文獻回顧、專家訪談、臨床註冊分析和檢驗步驟，確保了研究結果的可靠性。

本分析的調查方法整合了多種互補途徑，以確保其穩健性、有效性和實用性。此方法是基於對同行評審的臨床研究、指南和公開監管文件的結構化文獻綜述和綜合分析，旨在掌握目前的標準治療方案和新興證據。此外，還輔以一手研究，包括對臨床專家、影像專家、臨床實驗研究人員和供應鏈管理人員的訪談，以闡明研究結果的背景並驗證其與實際操作的契合度。

資料三角測量法用於整合不同的輸入資料並檢驗主題結論。透過查閱臨床試驗註冊庫和近期會議論文集，我們整理了正在進行的研發項目，並識別了新療法和診斷方法的發展趨勢。在適當情況下，我們會分析技術規格和產品標籤，以了解其功能、限制和整合要求。此外，研究調查方法還包括情境分析，以檢驗監管變化、報銷政策變化和供應鏈中斷等變數如何影響產品推廣應用的趨勢。

我們承認存在一些局限性，包括區域實踐模式的差異以及早期臨床證據的持續演變。為了克服這些局限性，我們以清晰的證據等級呈現觀察，並輔以專家意見。所有關鍵環節均指南倫理標準和資料完整性規範，並整合了保密的專家意見，以在確保資訊可操作性的同時保護匿名性。

策略性結論強調，要實際改善腦腫瘤治療，需要整合診斷、進行協作開發以及採用主導醫學方法。

總之，腦腫瘤的診斷和治療領域正處於一個關鍵的十字路口，技術進步、不斷演進的臨床範式和不斷變化的政策環境既帶來了機遇，也帶來了挑戰。整合診斷和定向治療是未來發展的核心，但其成功取決於臨床專科、監管機構、支付者和產業界的協同努力。影像學、分子譜分析和腫瘤免疫學的創新正在重新定義疾病分類和治療路徑，而供應鏈的韌性和策略夥伴關係關係對於維持醫療服務的可及性和規模至關重要。

相關人員投資於診斷和治療合作、積極管理商業性和監管風險並優先考慮真實世界證據產生的利益相關者，最有可能實現永續的臨床和經濟效益。我們迫切需要超越孤立的突破，轉向系統層面的整合，從而改善患者選擇、最佳化治療順序並保障患者的生活品質。這需要嚴謹的執行、清晰的價值論證以及以患者為中心的理念，將科學目標與可實現的臨床效益相結合。

目錄

第1章：序言

第2章調查方法

第3章執行摘要

第4章 市場概覽

第5章 市場洞察

  • 推出基於人工智慧的放射組學平台，用於個人化神經膠母細胞瘤治療計劃
  • 基於血液的液態生物檢體檢測方法的出現，為非侵入性檢測和監測腫瘤復發提供了可能。
  • 引入術中螢光導航手術技術以增強腫瘤邊緣切除效果
  • 靶向膠質瘤特異性抗原並具有更高穿透性的CAR-T細胞療法發展迅速。
  • 拓展分子影像劑的應用範圍，以實現對腫瘤代謝和治療反應的即時評估
  • 開發一種可植入式藥物輸送系統，用於在腦腫瘤中局部和持續釋放化療
  • 可攜式高場核磁共振造影系統在社區醫療保健中用於神經腫瘤診斷的商業化

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章 腦腫瘤診斷與治療市場（依治療方法）

  • 化療
    • 烷化劑
    • 抗代謝物
    • 鉑化合物
  • 免疫療法
    • CAR-T細胞療法
    • 查核點抑制劑
    • 疫苗療法
  • 放射治療
  • 外科手術
  • 標靶治療
    • 抗血管新生藥物
    • MTOR抑制劑
    • 蛋白酪氨酸激酶抑制劑

第9章 影像技術在腦腫瘤診斷與治療市場的應用

  • 電腦斷層掃描
  • 磁振造影
    • 擴散張量造影
    • 功能性磁振造影
    • 光譜學
  • 分子診斷
  • 正子斷層掃描
    • 胺基酸示踪劑
    • FDG
  • 超音波

第10章 依最終使用者分類的腦腫瘤診斷與治療市場

  • 門診手術中心
  • 診斷實驗室
  • 醫院
  • 研究所

第11章 按腫瘤類型分類的腦腫瘤診斷與治療市場

  • 聽神經瘤
  • 膠質瘤
  • 腦膜瘤
  • 腦下垂體瘤

第12章 依腫瘤分級分類的腦腫瘤診斷與治療市場

  • 優質
  • 低級

第13章 依患者年齡層分類的腦腫瘤診斷與治療市場

  • 成人
  • 老年人
  • 孩子們

第14章 各地區腦瘤診斷與治療市場

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第15章 腦腫瘤診斷與治療市場（依組別分類）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第16章 各國腦瘤診斷與治療市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第17章 競爭格局

  • 2024年市佔率分析
  • FPNV定位矩陣，2024
  • 競爭分析
    • Siemens Aktiengesellschaft
    • General Electric Company
    • Koninklijke Philips NV
    • F. Hoffmann-La Roche Ltd.
    • Novocure Limited
    • Novartis AG
    • Merck & Co., Inc.
    • Pfizer Inc.
    • Johnson & Johnson
    • Medtronic plc
Product Code: MRR-CA17E905E619

The Brain Tumor Diagnosis & Therapeutics Market is projected to grow by USD 3.73 billion at a CAGR of 9.65% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 1.78 billion
Estimated Year [2025] USD 1.95 billion
Forecast Year [2032] USD 3.73 billion
CAGR (%) 9.65%

A clear and compelling introduction to the current clinical, scientific, and health system forces reshaping brain tumor diagnosis and therapeutic innovation

Brain tumor diagnosis and therapeutics occupy a rapidly changing intersection of clinical urgency, scientific innovation, and health system transformation. Advances in molecular biology and imaging have reframed how clinicians classify neoplasms, enabling more precise diagnostic categories that inform individualized therapeutic strategies. At the same time, evolving surgical techniques, adjunctive radiation modalities, and a growing suite of targeted and immune-based therapies are reshaping treatment pathways across tumor types and patient age cohorts.

This landscape is defined by multidimensional collaboration among neurosurgeons, neuro-oncologists, radiologists, pathologists, and translational scientists. Technology convergence-combining genomic profiling, advanced MRI sequences, and functional imaging-now supports risk-adapted care and more informed clinical decision-making. However, significant unmet needs remain, particularly for aggressive high-grade tumors and rare pediatric variants where durable responses are limited and therapeutic windows are narrow.

Consequently, stakeholders are prioritizing integrated diagnostics and therapeutic development, with emphasis on biomarker-driven trials, minimally invasive monitoring, and real-world evidence generation. This report introduces the critical themes that govern current clinical practice, innovation trajectories, and health system adoption, setting the stage for the deeper analyses that follow and framing the practical implications for developers, providers, and payers.

Detailed analysis of the major technological, clinical, and care-delivery shifts that are redefining brain tumor diagnostics and therapeutic development across the care continuum

The landscape of brain tumor diagnosis and therapeutics is undergoing several transformative shifts that collectively alter how care is delivered and how products are developed. At the diagnostic level, high-resolution imaging and molecular pathology are moving beyond descriptive classification to enable precision phenotyping; this transition supports adaptive trial designs and targeted therapeutic strategies. Concurrently, immuno-oncology and cell-based therapies are progressing from experimental platforms to viable clinical options, prompting new considerations for safety monitoring, manufacturing scale, and long-term follow-up.

Imaging innovations, including diffusion tensor imaging, functional MRI, and amino acid PET tracers, are improving lesion characterization and treatment planning, thereby enabling more conservative resections and optimized radiation targeting. Surgical advances such as intraoperative visualization and fluorescence-guided resection are enhancing extent-of-resection while preserving function, which in turn changes adjuvant therapy decision-making. On the therapeutic front, combination regimens that pair targeted agents with immune-modulatory approaches are increasingly central to clinical development, necessitating more sophisticated biomarker strategies and companion diagnostics.

Additionally, digital health, machine learning, and real-world data are gaining prominence as tools for earlier detection, prognostic modeling, and post-market surveillance. These shifts create both opportunities and complexities: developers must navigate regulatory expectations for novel modalities while health systems must adapt infrastructure to support multidisciplinary workflows and advanced diagnostics. Transitioning from siloed innovation to integrated care pathways will determine which advances translate into meaningful improvements in patient outcomes.

Assessment of how recent tariff-driven trade measures could reshape supply chains, procurement, and adoption dynamics for brain tumor diagnostics and therapeutics in the United States

Policy interventions such as tariffs can exert a broad and cumulative influence on the ecosystem that supports brain tumor diagnostics and therapeutics. Import measures affecting imaging equipment, reagents for molecular testing, and specialized consumables used in advanced surgical and cell therapy manufacturing can increase direct procurement costs and extend lead times for critical tools. These pressures ripple through hospital capital planning and clinical trial logistics, potentially delaying adoption of newer diagnostic platforms and constraining the pace at which advanced therapeutic modalities are scaled.

Manufacturers and health systems may respond by accelerating localization of supply chains and investing in domestic manufacturing capacity for high-value inputs. While onshoring can mitigate future trade-related disruptions, it also requires significant capital investment and strategic partnerships to ensure quality and regulatory compliance. For smaller developers and academic centers, increased import costs may shift prioritization toward technologies with lower capital intensity or toward licensing agreements that reduce upfront hardware requirements.

In the research domain, tariffs can alter the economics of multicenter trials that rely on uniform imaging or molecular platforms, complicating harmonization and data comparability. Clinical collaborators may need to renegotiate service contracts or adapt protocols to account for equipment heterogeneity. Ultimately, stakeholders should view tariff-related impacts as a catalyst for supply diversification, strategic procurement, and closer collaboration between industry, clinical networks, and policy makers to safeguard access to critical diagnostic and therapeutic innovations.

Insightful segmentation synthesis explaining how therapeutic modalities, imaging innovations, end users, tumor typologies, grades, and patient age groups collectively inform strategic priorities

A segmentation-aware perspective clarifies where scientific advances and commercial opportunities are concentrated across diagnostic and therapeutic axes. Within therapeutic modality, chemotherapy, immunotherapy, radiation therapy, surgery, and targeted therapy each contribute distinct mechanisms and clinical roles; chemotherapy includes alkylating agents, antimetabolites, and platinum compounds that remain core to many regimens, while targeted therapies emphasize antiangiogenic agents, mTOR inhibitors, and tyrosine kinase inhibitors focused on molecular vulnerabilities. Immunotherapy encompasses CAR T-cell therapy, checkpoint inhibitors, and vaccine platforms that are driving combination strategies and necessitating specialized manufacturing and safety monitoring. These modalities interact with tumor biology and patient factors to shape treatment sequencing and trial design.

On the diagnostic imaging side, the market is organized across computed tomography, magnetic resonance imaging, molecular diagnostics, positron emission tomography, and ultrasound. Magnetic resonance imaging further segments into diffusion tensor imaging, functional MRI, and spectroscopy that enhance structural and functional assessment, whereas positron emission tomography leverages amino acid tracers and FDG for improved metabolic evaluation. End users are defined across ambulatory surgical centers, diagnostic laboratories, hospitals, and research institutes, each exhibiting different capital intensity, workflow needs, and decision-making authority for technology adoption.

Tumor-type segmentation spans acoustic neuroma, glioma, meningioma, and pituitary tumor with divergent clinical courses and regulatory pathways, and tumor-grade classification into high grade and low grade remains pivotal for prognosis and treatment aggressiveness. Patient age cohorts-adult, geriatric, and pediatric-introduce distinct biological considerations, dosing imperatives, and regulatory protections, especially in pediatric populations where long-term neurocognitive outcomes are critical. Integrating these segmentation lenses reveals that investment and clinical emphasis are concentrated where molecularly targetable biology, unmet clinical need, and feasible delivery pathways converge.

Comprehensive regional analysis describing how Americas, Europe Middle East & Africa, and Asia-Pacific each shape clinical adoption, regulatory strategy, and commercialization pathways

Geographic dynamics are a key determinant of technology adoption, regulatory pathways, and commercial strategy. In the Americas, clinical trial capacity, venture investment, and integrated care networks drive rapid uptake of novel diagnostics and therapeutics, complemented by a strong ecosystem for biotech translation and advanced hospital infrastructure. The United States in particular remains a focal point for early-phase studies and commercial launches, with regional reimbursement and policy changes influencing speed of access.

The Europe, Middle East & Africa region exhibits heterogeneous healthcare systems and regulatory environments, with pockets of excellence in advanced neuro-oncology centers and national research networks. European regulatory frameworks emphasize rigorous evidence and cost-effectiveness, while several Gulf and North African markets are investing in tertiary care capacity, creating selective demand for high-value interventions. These variations require tailored market access strategies and localized evidence generation.

Asia-Pacific is characterized by rapid adoption curves in urban centers, growing domestic manufacturing capabilities, and demographic trends that expand demand for neuro-oncology services. Cost sensitivity and diverse reimbursement landscapes in the region necessitate flexible pricing and partnership models, while several Asian countries are emerging as key sites for late-stage clinical trials due to patient volume and operational efficiencies. Cross-regional collaboration and technology transfer are increasingly important to ensure consistent standards of care and to scale innovations globally.

Actionable corporate intelligence outlining how strategic partnerships, platform integration, and manufacturing investments differentiate companies in brain tumor diagnostics and therapeutic development

Company behavior in this sector is characterized by strategic partnerships, platform extension, and targeted investments in manufacturing and digital capabilities. Firms that combine diagnostic platforms with therapeutic pipelines or that secure companion diagnostic linkages gain competitive advantage by aligning development and commercialization timelines. Collaboration between biopharma developers and diagnostics or imaging vendors is intensifying, driven by the need for biomarker-driven enrollment and real-time response assessment.

Key corporate strategies include forming consortiums to de-risk early clinical development, outsourcing specialized manufacturing for cell and gene therapies, and investing in cloud-based platforms for imaging analysis and longitudinal outcome monitoring. Mergers and acquisitions continue to be a lever for rapid capability acquisition, particularly for companies seeking to integrate molecular testing, imaging analytics, and clinical decision support into a coherent offering. Smaller innovators are frequently acquired or enter co-development agreements to scale manufacturing and regulatory expertise, while larger organizations focus on platform consolidation and global market access.

Across the competitive landscape, agility in forging payer relationships and demonstrating health economic value is becoming as important as scientific differentiation. Companies that proactively address real-world implementation challenges, simplify clinical workflows, and provide training and support to health systems are more likely to achieve durable adoption and sustained commercial performance.

Clear and prioritized recommendations for industry leaders to accelerate development, mitigate commercial risks, and demonstrate clinical and economic value in brain tumor care

Industry leaders should adopt a set of pragmatic, actionable priorities to convert scientific promise into clinical impact and sustainable business models. First, prioritize investment in integrated diagnostics that link molecular profiling with advanced imaging to enable precise patient selection and adaptive trial enrollment. This approach reduces development risk and enhances the likelihood of demonstrating meaningful clinical benefit. Second, diversify supply chains and consider regional manufacturing partnerships to mitigate trade and tariff exposure while ensuring continuity for high-value inputs.

Third, pursue combination strategies deliberately by aligning regulatory and safety pathways early in development and by establishing standardized biomarker strategies to streamline approval and reimbursement. Fourth, engage payers and health technology assessment bodies early to define evidence requirements and case definitions that support value-based contracting. Fifth, invest in real-world evidence and data infrastructure that captures longitudinal outcomes, quality-of-life metrics, and health economic endpoints to support uptake and formulary inclusion.

Finally, strengthen cross-sector collaborations with academic centers, patient advocacy organizations, and surgical and radiology networks to accelerate clinical adoption, improve trial recruitment, and ensure that innovations address practical care delivery constraints. These steps will help organizations reduce time to market, enhance value demonstration, and ultimately improve patient outcomes in a complex therapeutic area.

Rigorous and transparent research methodology combining literature synthesis, expert interviews, clinical registry analysis, and validation steps to ensure trustworthy insights

The research methodology underpinning this analysis integrates multiple complementary approaches to ensure robustness, validity, and practical relevance. The foundation comprises structured literature review and synthesis of peer-reviewed clinical studies, guidelines, and publicly available regulatory documents to capture the current standard of care and emergent evidence. This secondary research is augmented with targeted primary research, including interviews with clinical experts, imaging specialists, trial investigators, and supply chain managers to contextualize findings and confirm operational realities.

Data triangulation is used to reconcile differing inputs and to validate thematic conclusions. Clinical trial registries and recent conference proceedings are reviewed to map active development programs and to identify nascent therapeutic and diagnostic trends. Where appropriate, technical specifications and product labeling are analyzed to understand capabilities, limitations, and integration requirements. The methodology also includes scenario analysis to test how variables such as regulatory shifts, reimbursement changes, or supply-chain disruptions might affect adoption curves.

Limitations are acknowledged, including variability in regional practice patterns and the evolving nature of early-phase clinical evidence. To address these constraints, findings are presented with clarity about evidence level and are supplemented by expert judgment. Ethical standards and data integrity practices guide all primary engagements, and confidential input from experts is synthesized to preserve anonymity while preserving actionable insight.

Strategic conclusion emphasizing the need for integrated diagnostics, coordinated development, and evidence-driven adoption to realize meaningful improvements in brain tumor care

In conclusion, the field of brain tumor diagnosis and therapeutics stands at a pivotal juncture where converging technological advances, evolving clinical paradigms, and shifting policy environments create both opportunity and complexity. Integrated diagnostics and precision-directed therapeutics are central to future progress, but their successful translation will depend on coordinated efforts across clinical specialties, regulators, payers, and industry. Innovations in imaging, molecular profiling, and immuno-oncology are redefining disease classification and treatment pathways, while supply-chain resilience and strategic partnerships are essential to sustain access and scale.

Stakeholders that invest in linkage between diagnostics and therapeutics, proactively manage commercial and regulatory risk, and prioritize real-world evidence generation will be best positioned to realize durable clinical and economic outcomes. The imperative is to move beyond isolated breakthroughs toward systems-level integration that improves patient selection, optimizes therapeutic sequencing, and preserves quality of life. Doing so will require disciplined execution, clear demonstration of value, and a patient-centered focus that aligns scientific ambition with deliverable clinical benefit.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Adoption of AI-driven radiomics platforms for personalized glioblastoma treatment planning
  • 5.2. Emergence of blood-based liquid biopsy assays for noninvasive detection and monitoring of tumor recurrence
  • 5.3. Implementation of intraoperative fluorescence-guided surgery techniques to enhance tumor margin resection
  • 5.4. Rapid growth of CAR T-cell therapies engineered to target glioma-specific antigens with improved penetration
  • 5.5. Expansion of molecular imaging agents enabling real-time assessment of tumor metabolism and therapeutic response
  • 5.6. Development of implantable drug delivery systems for localized and sustained release of chemotherapeutics in brain tumors
  • 5.7. Commercialization of portable high-field MRI devices for point-of-care neuro-oncology diagnostics in community settings

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Brain Tumor Diagnosis & Therapeutics Market, by Therapeutic Modality

  • 8.1. Chemotherapy
    • 8.1.1. Alkylating Agents
    • 8.1.2. Antimetabolites
    • 8.1.3. Platinum Compounds
  • 8.2. Immunotherapy
    • 8.2.1. CAR T-Cell Therapy
    • 8.2.2. Checkpoint Inhibitors
    • 8.2.3. Vaccine Therapy
  • 8.3. Radiation Therapy
  • 8.4. Surgery
  • 8.5. Targeted Therapy
    • 8.5.1. Antiangiogenic Agents
    • 8.5.2. MTOR Inhibitors
    • 8.5.3. Tyrosine Kinase Inhibitors

9. Brain Tumor Diagnosis & Therapeutics Market, by Imaging Technology

  • 9.1. Computed Tomography
  • 9.2. Magnetic Resonance Imaging
    • 9.2.1. Diffusion Tensor Imaging
    • 9.2.2. Functional MRI
    • 9.2.3. Spectroscopy
  • 9.3. Molecular Diagnostics
  • 9.4. Positron Emission Tomography
    • 9.4.1. Amino Acid Tracers
    • 9.4.2. FDG
  • 9.5. Ultrasound

10. Brain Tumor Diagnosis & Therapeutics Market, by End User

  • 10.1. Ambulatory Surgical Centers
  • 10.2. Diagnostic Laboratories
  • 10.3. Hospitals
  • 10.4. Research Institutes

11. Brain Tumor Diagnosis & Therapeutics Market, by Tumor Type

  • 11.1. Acoustic Neuroma
  • 11.2. Glioma
  • 11.3. Meningioma
  • 11.4. Pituitary Tumor

12. Brain Tumor Diagnosis & Therapeutics Market, by Tumor Grade

  • 12.1. High Grade
  • 12.2. Low Grade

13. Brain Tumor Diagnosis & Therapeutics Market, by Patient Age Group

  • 13.1. Adult
  • 13.2. Geriatric
  • 13.3. Pediatric

14. Brain Tumor Diagnosis & Therapeutics Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. Brain Tumor Diagnosis & Therapeutics Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. Brain Tumor Diagnosis & Therapeutics Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. Competitive Landscape

  • 17.1. Market Share Analysis, 2024
  • 17.2. FPNV Positioning Matrix, 2024
  • 17.3. Competitive Analysis
    • 17.3.1. Siemens Aktiengesellschaft
    • 17.3.2. General Electric Company
    • 17.3.3. Koninklijke Philips N.V.
    • 17.3.4. F. Hoffmann-La Roche Ltd.
    • 17.3.5. Novocure Limited
    • 17.3.6. Novartis AG
    • 17.3.7. Merck & Co., Inc.
    • 17.3.8. Pfizer Inc.
    • 17.3.9. Johnson & Johnson
    • 17.3.10. Medtronic plc

LIST OF FIGURES

  • FIGURE 1. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY THERAPEUTIC MODALITY, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY THERAPEUTIC MODALITY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY IMAGING TECHNOLOGY, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY IMAGING TECHNOLOGY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY TUMOR TYPE, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY TUMOR TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY TUMOR GRADE, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY TUMOR GRADE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2024 VS 2032 (%)
  • FIGURE 13. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. AMERICAS BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. NORTH AMERICA BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. LATIN AMERICA BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. EUROPE BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. MIDDLE EAST BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. AFRICA BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASIA-PACIFIC BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. ASEAN BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. GCC BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. EUROPEAN UNION BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. BRICS BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. G7 BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. NATO BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 30. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 31. BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 32. BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY THERAPEUTIC MODALITY, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY THERAPEUTIC MODALITY, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY ALKYLATING AGENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY ALKYLATING AGENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY ALKYLATING AGENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY ALKYLATING AGENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY ALKYLATING AGENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY ALKYLATING AGENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY ANTIMETABOLITES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY ANTIMETABOLITES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY ANTIMETABOLITES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY ANTIMETABOLITES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY ANTIMETABOLITES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY ANTIMETABOLITES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY PLATINUM COMPOUNDS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY PLATINUM COMPOUNDS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY PLATINUM COMPOUNDS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY PLATINUM COMPOUNDS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY PLATINUM COMPOUNDS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY PLATINUM COMPOUNDS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY CAR T-CELL THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY CAR T-CELL THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY CAR T-CELL THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY CAR T-CELL THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY CAR T-CELL THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY CAR T-CELL THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY CHECKPOINT INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY CHECKPOINT INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY CHECKPOINT INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY CHECKPOINT INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY CHECKPOINT INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY CHECKPOINT INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY VACCINE THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY VACCINE THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY VACCINE THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY VACCINE THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY VACCINE THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY VACCINE THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY RADIATION THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY RADIATION THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY RADIATION THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY RADIATION THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY RADIATION THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY RADIATION THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY SURGERY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY SURGERY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY SURGERY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY SURGERY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY SURGERY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY SURGERY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY ANTIANGIOGENIC AGENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY ANTIANGIOGENIC AGENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY ANTIANGIOGENIC AGENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY ANTIANGIOGENIC AGENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY ANTIANGIOGENIC AGENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY ANTIANGIOGENIC AGENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY MTOR INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY MTOR INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY MTOR INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY MTOR INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY MTOR INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY MTOR INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY IMAGING TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY IMAGING TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY COMPUTED TOMOGRAPHY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY COMPUTED TOMOGRAPHY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY COMPUTED TOMOGRAPHY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY COMPUTED TOMOGRAPHY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY COMPUTED TOMOGRAPHY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY COMPUTED TOMOGRAPHY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY DIFFUSION TENSOR IMAGING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY DIFFUSION TENSOR IMAGING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY DIFFUSION TENSOR IMAGING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY DIFFUSION TENSOR IMAGING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY DIFFUSION TENSOR IMAGING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY DIFFUSION TENSOR IMAGING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY FUNCTIONAL MRI, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY FUNCTIONAL MRI, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY FUNCTIONAL MRI, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY FUNCTIONAL MRI, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY FUNCTIONAL MRI, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY FUNCTIONAL MRI, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY SPECTROSCOPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY SPECTROSCOPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY SPECTROSCOPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY SPECTROSCOPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY SPECTROSCOPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY SPECTROSCOPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY POSITRON EMISSION TOMOGRAPHY, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY POSITRON EMISSION TOMOGRAPHY, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY POSITRON EMISSION TOMOGRAPHY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY POSITRON EMISSION TOMOGRAPHY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY POSITRON EMISSION TOMOGRAPHY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY POSITRON EMISSION TOMOGRAPHY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY POSITRON EMISSION TOMOGRAPHY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY POSITRON EMISSION TOMOGRAPHY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY AMINO ACID TRACERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY AMINO ACID TRACERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY AMINO ACID TRACERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY AMINO ACID TRACERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY AMINO ACID TRACERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY AMINO ACID TRACERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY FDG, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY FDG, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY FDG, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY FDG, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY FDG, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY FDG, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY ULTRASOUND, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY ULTRASOUND, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY ULTRASOUND, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY ULTRASOUND, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY ULTRASOUND, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY ULTRASOUND, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY TUMOR TYPE, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY TUMOR TYPE, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY ACOUSTIC NEUROMA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY ACOUSTIC NEUROMA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY ACOUSTIC NEUROMA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY ACOUSTIC NEUROMA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY ACOUSTIC NEUROMA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY ACOUSTIC NEUROMA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY GLIOMA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY GLIOMA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 199. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY GLIOMA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY GLIOMA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 201. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY GLIOMA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 202. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY GLIOMA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 203. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY MENINGIOMA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 204. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY MENINGIOMA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 205. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY MENINGIOMA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 206. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY MENINGIOMA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 207. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY MENINGIOMA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 208. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY MENINGIOMA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 209. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY PITUITARY TUMOR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 210. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY PITUITARY TUMOR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 211. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY PITUITARY TUMOR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 212. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY PITUITARY TUMOR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 213. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY PITUITARY TUMOR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 214. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY PITUITARY TUMOR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 215. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY TUMOR GRADE, 2018-2024 (USD MILLION)
  • TABLE 216. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY TUMOR GRADE, 2025-2032 (USD MILLION)
  • TABLE 217. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY HIGH GRADE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 218. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY HIGH GRADE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 219. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY HIGH GRADE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 220. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY HIGH GRADE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 221. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY HIGH GRADE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 222. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY HIGH GRADE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 223. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY LOW GRADE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 224. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY LOW GRADE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 225. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY LOW GRADE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 226. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY LOW GRADE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 227. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY LOW GRADE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 228. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY LOW GRADE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 229. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 230. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 231. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY ADULT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 232. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY ADULT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 233. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY ADULT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 234. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY ADULT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 235. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY ADULT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 236. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY ADULT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 237. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY GERIATRIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 238. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY GERIATRIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 239. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY GERIATRIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 240. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY GERIATRIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 241. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY GERIATRIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 242. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY GERIATRIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 243. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 244. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY PEDIATRIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 245. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY PEDIATRIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 246. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY PEDIATRIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 247. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY PEDIATRIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 248. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY PEDIATRIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 249. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 250. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 251. AMERICAS BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 252. AMERICAS BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 253. AMERICAS BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY THERAPEUTIC MODALITY, 2018-2024 (USD MILLION)
  • TABLE 254. AMERICAS BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY THERAPEUTIC MODALITY, 2025-2032 (USD MILLION)
  • TABLE 255. AMERICAS BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 256. AMERICAS BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 257. AMERICAS BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 258. AMERICAS BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 259. AMERICAS BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2024 (USD MILLION)
  • TABLE 260. AMERICAS BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2025-2032 (USD MILLION)
  • TABLE 261. AMERICAS BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY IMAGING TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 262. AMERICAS BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY IMAGING TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 263. AMERICAS BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, 2018-2024 (USD MILLION)
  • TABLE 264. AMERICAS BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, 2025-2032 (USD MILLION)
  • TABLE 265. AMERICAS BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY POSITRON EMISSION TOMOGRAPHY, 2018-2024 (USD MILLION)
  • TABLE 266. AMERICAS BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY POSITRON EMISSION TOMOGRAPHY, 2025-2032 (USD MILLION)
  • TABLE 267. AMERICAS BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 268. AMERICAS BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 269. AMERICAS BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY TUMOR TYPE, 2018-2024 (USD MILLION)
  • TABLE 270. AMERICAS BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY TUMOR TYPE, 2025-2032 (USD MILLION)
  • TABLE 271. AMERICAS BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY TUMOR GRADE, 2018-2024 (USD MILLION)
  • TABLE 272. AMERICAS BRAIN TUMOR